Annual Report

Overview

The report highlights ProQR's 2017 progress in its RNA therapeutics pipeline, including completion of the eluforsen trial, initiation of QR-110 clinical testing, and preparation for QR-313's first human study. It also describes validation of the Axiomer RNA-editing platform through in vivo proof of concept and the creation of Amylon Therapeutics as a majority-owned CNS-focused company. The report presents patient-centric drug development and continued expansion of rare-disease programs as the company's central direction.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2017
Period: Ends 31 December 2017
Publication date: 30 March 2018
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services